This new Medicare program offers obesity drugs for $50 a month. Here's what you need to know
Medicare has launched a new pilot program called Bridge that allows eligible seniors to access GLP-1 obesity drugs from Novo Nordisk and Eli Lilly for $50 per month copays, starting this week. This represents a major policy shift as Medicare has historically excluded obesity medications from coverage, and could potentially reach millions of beneficiaries and expand access to drugs that normally cost hundreds of dollars monthly.
Summary
For years, popular weight loss drugs known as GLP-1s have been financially inaccessible to most older Americans on Medicare, with monthly costs reaching hundreds of dollars. This week marks a significant change with the launch of the Bridge program, a temporary Medicare pilot initiative that creates a new pathway for coverage of obesity medications. The program specifically targets patients meeting certain criteria, including those with a BMI over 35 and individuals with obesity-related health conditions. Under this program, eligible Medicare beneficiaries can now access GLP-1 drugs from pharmaceutical companies Novo Nordisk and Eli Lilly with a copay of just $50 per month. This represents a major policy reversal for Medicare, which has traditionally barred coverage of medications prescribed solely for weight loss and obesity treatment. The program could dramatically expand patient access to these medications and help prevent costly health complications associated with obesity. Industry estimates suggest the Bridge program could eventually reach as many as 20 million new patients, representing substantial market expansion for both drug manufacturers. With more than 69 million Americans currently enrolled in Medicare, officials anticipate that several million beneficiaries will join the Bridge program immediately upon launch. However, the rollout presents operational challenges. The process requires physicians to submit prior authorization requests to verify that patients meet eligibility requirements before coverage is approved. Healthcare providers have expressed concerns that the influx of new patients could strain already busy clinics and pharmacies, with some doctors cautioning that the healthcare system will need patience during the initial rollout period as patients eagerly begin these medications.
Key Insights
- Medicare has historically barred coverage of medications prescribed solely for obesity, but the new Bridge program creates a temporary pathway that breaks this traditional policy restriction
- GLP-1 obesity drugs from Novo Nordisk and Eli Lilly normally cost hundreds of dollars per month, but the Bridge program reduces the copay to $50 monthly for eligible patients
- Novo Nordisk and Eli Lilly estimate the Bridge program could reach as many as 20 million new patients, representing a major market expansion opportunity
- Physicians must submit prior authorization requests to confirm beneficiary eligibility before coverage approval, adding an administrative step to the enrollment process
- Physicians anticipate that the wave of new patients entering the program could create strain on already busy clinics and pharmacies over the coming months
Topics
Transcript
[0:00] Popular weight loss drugs have remained out of reach for most older Americans in Medicare for years. That's because GLP-1s can cost hundreds of dollars per month, but that changes this week. Starting Wednesday, millions of eligible Medicare patients can access GLP-1 obesity drugs from [music] Novo Nordisk and Eli Lilly for a copay of just $50 per month. It's a major shift for a federal program that has traditionally barred coverage of medications prescribed solely for obesity. So, what happened? Well, there's a new Medicare pilot program called Bridge that's creating a temporary pathway for [0:30] coverage. Patients who meet certain requirements, including those with a BMI of over 35 and people with certain obesity-related conditions, [music] may…
Full transcript available for MurmurCast members
Sign Up to AccessMore from CNBC
GTA 6's Billion-Dollar Hype Machine
GTA VI is projected to be the most anticipated game launch in history, with an estimated $1 billion+ development budget expected to be recouped on day one through 25 million pre-sales at $100 each. The game's release is anticipated to have massive economic ripple effects across entertainment, streaming, and traditional business sectors, with nearly 1 in 3 gamers planning to purchase it.
The rise, reinvention and uncertain future of Nvidia without Jensen Huang
Nvidia founder Jensen Huang has been removed as CEO amid allegations of multiple affairs, including with direct reports, and connections to Alice Wong, who may be a Chinese spy involved in distributing AI chips across Southeast Asia. The scandal represents the company's biggest crisis in its 33-year history, occurring during a period of strict U.S. export controls on advanced chips to China.
Could Democratic Gains Bring Tariff Relief For Canada?
Following Democrats' 2026 midterm victories, Canadian investors anticipate potential tariff relief, but progress will likely be slow given President Trump's remaining two years in office and the complexity of trade negotiations. While some sectors like steel, lumber, and agriculture could benefit from reduced tariffs, Rust Belt Democrats and security concerns may limit the scope of relief.
Nvidia In Crisis: The Rise Of Jensen Huang’s Empire At The Center Of The AI Boom
This documentary examines Nvidia's rise to dominance in AI computing and the recent crisis surrounding founder Jensen Huang's resignation following allegations of affairs and potential involvement with a figure connected to Chinese AI chip diversion schemes. The narrative explores how Huang built Nvidia from a graphics card startup in 1993 into a $150+ billion company at the center of the AI boom, while also detailing geopolitical risks, export control complications, and questions about the company's future without its iconic founder.
How Democrats Won Back Union Voters
Democrats have dramatically reversed declining support among union voters, winning union households by 22 percentage points in the 2026 midterms compared to just 8 points in 2024. This turnaround was driven by aggressive union organizing efforts and increased voter enthusiasm, though questions remain about sustaining this advantage in future presidential elections.